(MRSP) in dogs, poses significant challenges for effective treatment options in veterinary practice. Here, we show that NCL195, a member of a novel class of pyrimidine compounds, exhibits antibacterial activity against 160 MRSP isolates collected from dogs from multiple clinical cases. Additionally, no resistant mutants developed during prolonged serial passage experiments, and NCL195 showed low lysis of dog and sheep red blood cells. Developing NCL195 as an "animal-only" drug promotes the "responsibility" and "refinement" principles of antimicrobial stewardship.
Bista et al. (Thu,) studied this question.